Atypical Chronic Myeloid Leukemia (ACML)

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Atypical Chronic Myeloid Leukemia

MalaCards integrated aliases for Atypical Chronic Myeloid Leukemia:

Name: Atypical Chronic Myeloid Leukemia 12 58 29 6 15
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 43 71
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 12
Subacute Myeloid Leukemia 58
Atypical Cml 12
Acml 12


Orphanet epidemiological data:

atypical chronic myeloid leukemia
Age of onset: Adult;


Orphanet: 58  
Rare haematological diseases

External Ids:

Disease Ontology 12 DOID:0060597
MeSH 43 D054438
NCIt 49 C3176 C3519
ICD10 32 C92.2 C92.20
MESH via Orphanet 44 D054438
ICD10 via Orphanet 33 C92.2
UMLS via Orphanet 72 C0349640 C1292772
Orphanet 58 ORPHA98824
UMLS 71 C1292772

Summaries for Atypical Chronic Myeloid Leukemia

Disease Ontology : 12 A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.

MalaCards based summary : Atypical Chronic Myeloid Leukemia, also known as leukemia, myeloid, chronic, atypical, bcr-abl negative, is related to leukemia, chronic myeloid and hypereosinophilic syndrome. An important gene associated with Atypical Chronic Myeloid Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Decitabine and Mercaptopurine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Atypical chronic myeloid leukemia (aCML) is a type of leukemia. It is a heterogeneous disorder belonging... more...

Related Diseases for Atypical Chronic Myeloid Leukemia

Diseases related to Atypical Chronic Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic myeloid 30.5 U2AF1 SETBP1 RUNX1 PDGFRB PDGFRA LUC7L2
2 hypereosinophilic syndrome 30.1 PDGFRB PDGFRA JAK2 FGFR1 ABL1
3 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.0 RUNX1 ETV6
4 refractory anemia 29.9 TET2 RUNX1 ASXL1
5 thrombocytosis 29.8 U2AF1 TET2 JAK2 ASXL1
6 thrombocytopenia 29.7 U2AF1 RUNX1 PDGFRA JAK2 ETV6
7 myeloid leukemia 29.7 U2AF1 TET2 RUNX1 PCM1 JAK2 ETV6
8 leukemia 29.6 U2AF1 RUNX1 JAK2 FGFR1 ETV6 CSF3R
9 mastocytosis 28.9 TET2 SRSF2 PDGFRB PDGFRA JAK2 FGFR1
10 chronic neutrophilic leukemia 28.8 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 JAK2
11 systemic mastocytosis 28.6 TET2 SRSF2 PDGFRB PDGFRA JAK2 FGFR1
12 leukemia, acute lymphoblastic 28.6 U2AF1 RUNX1 PTHLH JAK2 ETV6 CSF3R
13 blood platelet disease 28.6 U2AF1 RUNX1 RARS1 LUC7L2 JAK2 ASXL1
14 juvenile myelomonocytic leukemia 28.3 U2AF1 TET2 SETBP1 RUNX1 PDGFRB PDGFRA
15 myeloproliferative neoplasm 28.1 U2AF1 TET2 RUNX1 PDGFRB PDGFRA LUC7L2
16 chronic myelomonocytic leukemia 27.8 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PDGFRB
17 myelodysplastic syndrome 27.6 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PDGFRB
18 chronic leukemia 25.9 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 RARS1
19 myelodysplastic/myeloproliferative neoplasm 25.6 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 RARS1
20 leukemia, acute myeloid 25.3 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 RUNX1
21 subacute myeloid leukemia 12.7
22 acute erythroid leukemia 10.4 PCM1 JAK2
23 hypereosinophilic syndrome, idiopathic 10.4 PDGFRB PDGFRA
24 lymphoblastic leukemia, acute, with lymphomatous features 10.3 JAK2 FGFR1 ABL1
25 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.3 PDGFRB PDGFRA FGFR1
26 splenomegaly 10.3
27 core binding factor acute myeloid leukemia 10.2 RUNX1 JAK2
28 dermatofibrosarcoma protuberans 10.2 PDGFRB PDGFRA ABL1
29 8p11 myeloproliferative syndrome 10.2 RUNX1 PDGFRB FGFR1
30 myeloproliferative disorder, chronic, with eosinophilia 10.2 PDGFRB ETV6
31 endomyocardial fibrosis 10.2 PDGFRB PDGFRA
32 graft-versus-host disease 10.2
33 acute graft versus host disease 10.2
34 chromosomal triplication 10.2
35 adult astrocytic tumour 10.1 PDGFRA LUC7L2
36 testicular leukemia 10.1 ETV6 ABL1
37 cerebellar angioblastoma 10.1 PDGFRA ETV6
38 lymphocytic leukemia 10.1
39 mental retardation, autosomal dominant 33 10.1 JAK2 ETV6 ABL1
40 large cell carcinoma 10.1 PTHLH PDGFRA FGFR1 ABL1
41 amegakaryocytic thrombocytopenia, congenital 10.0 U2AF1 LUC7L2 JAK2
42 gastrointestinal stromal tumor 10.0 PDGFRB PDGFRA JAK2 ABL1
43 polycythemia 10.0 TET2 JAK2 ASXL1 ABL1
44 megakaryocytic leukemia 10.0 U2AF1 RUNX1 JAK2
45 blood coagulation disease 10.0 U2AF1 LUC7L2 JAK2
46 cebpa-associated familial acute myeloid leukemia 10.0 RUNX1 JAK2 ETV6
47 systemic mastocytosis with associated hematologic neoplasm 10.0 TET2 SRSF2 ASXL1
48 acquired von willebrand syndrome 10.0 U2AF1 JAK2
49 childhood leukemia 10.0 RUNX1 ETV6 ABL1
50 leukemia, chronic lymphocytic 9.9

Graphical network of the top 20 diseases related to Atypical Chronic Myeloid Leukemia:

Diseases related to Atypical Chronic Myeloid Leukemia

Symptoms & Phenotypes for Atypical Chronic Myeloid Leukemia

GenomeRNAi Phenotypes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.64 PDGFRA
2 Decreased viability GR00221-A-1 10.64 ABL1 ETNK1 PDGFRA PDGFRB FGFR1
3 Decreased viability GR00221-A-2 10.64 ABL1 ETNK1 FGFR1 JAK2 RYK
4 Decreased viability GR00221-A-3 10.64 ABL1 ETNK1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 10.64 ETNK1 PDGFRA PDGFRB RYK
6 Decreased viability GR00342-S-1 10.64 ABL1 ETNK1 PDGFRB RYK
7 Decreased viability GR00342-S-2 10.64 ABL1 RYK
8 Decreased viability GR00342-S-3 10.64 ABL1 RYK
9 Decreased viability GR00402-S-2 10.64 ABL1 ETNK1 PDGFRA PDGFRB FGFR1 JAK2
10 Increased cell viability after pRB stimulation GR00230-A-1 8.92 ABL1 ETNK1 PDGFRB RYK

MGI Mouse Phenotypes related to Atypical Chronic Myeloid Leukemia:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 ABL1 ASXL1 CSF3R FGFR1 JAK2 PCM1
2 cellular MP:0005384 10.27 ABL1 ASXL1 CSF3R ETV6 FGFR1 JAK2
3 hematopoietic system MP:0005397 10.25 ABL1 ASXL1 CSF3R ETNK1 ETV6 FGFR1
4 cardiovascular system MP:0005385 10.21 ABL1 ETV6 FGFR1 JAK2 PDGFRA PDGFRB
5 immune system MP:0005387 10.21 ABL1 ASXL1 CSF3R ETNK1 ETV6 FGFR1
6 endocrine/exocrine gland MP:0005379 10.17 ABL1 ASXL1 ETV6 FGFR1 JAK2 PDGFRA
7 mortality/aging MP:0010768 10.1 ABL1 ASXL1 CSF3R ETV6 FGFR1 JAK2
8 craniofacial MP:0005382 10.08 ABL1 ASXL1 FGFR1 PCM1 PDGFRA PDGFRB
9 digestive/alimentary MP:0005381 10.06 ABL1 ASXL1 ETV6 FGFR1 PDGFRA PDGFRB
10 integument MP:0010771 9.97 ETV6 FGFR1 JAK2 PCM1 PDGFRA PDGFRB
11 neoplasm MP:0002006 9.7 ASXL1 ETV6 JAK2 PDGFRA PTHLH RUNX1
12 normal MP:0002873 9.61 ABL1 ETV6 FGFR1 JAK2 PDGFRA PDGFRB
13 skeleton MP:0005390 9.32 ABL1 ASXL1 FGFR1 JAK2 PCM1 PDGFRA

Drugs & Therapeutics for Atypical Chronic Myeloid Leukemia

Drugs for Atypical Chronic Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
Mercaptopurine Approved Phase 3 50-44-2 667490
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
Hydroxyurea Approved Phase 3 127-07-1 3657
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Idarubicin Approved Phase 3 58957-92-9 42890
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
Daunorubicin Approved Phase 3 20830-81-3 30323
Thioguanine Approved Phase 3 154-42-7 2723601
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
Acyclovir Approved Phase 3 59277-89-3 2022
Mycophenolic acid Approved Phase 3 24280-93-1 446541
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
Polyestradiol phosphate Approved Phase 3 28014-46-2
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Interferon-alpha Phase 3
23 interferons Phase 3
24 Anesthetics, Dissociative Phase 3
25 Excitatory Amino Acid Antagonists Phase 3
26 Excitatory Amino Acids Phase 3
27 Keratolytic Agents Phase 3
28 Analgesics Phase 3
29 Cola Phase 3
30 Liver Extracts Phase 3
31 Narcotics Phase 3
32 Anesthetics Phase 3
33 Adjuvants, Anesthesia Phase 3
34 Analgesics, Opioid Phase 3
35 Anesthetics, General Phase 3
36 Central Nervous System Depressants Phase 3
37 Anesthetics, Intravenous Phase 3
38 Ophthalmic Solutions Phase 3
39 valacyclovir Phase 3
40 Antitubercular Agents Phase 3
41 Antibiotics, Antitubercular Phase 3
42 Topoisomerase Inhibitors Phase 3
43 Contraceptive Agents Phase 3
44 Norgestimate, ethinyl estradiol drug combination Phase 3
45 Estradiol 17 beta-cypionate Phase 3
46 Contraceptives, Oral, Combined Phase 3
47 Contraceptives, Oral Phase 3
48 Estradiol 3-benzoate Phase 3
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
Arsenic trioxide Approved, Investigational Phase 1, Phase 2 1327-53-3 518740

Interventional clinical trials:

(show top 50) (show all 205)
# Name Status NCT ID Phase Drugs
1 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
2 Randomized Multicenter Treatment Optimization Study In Chronic Myeloid Leukemia (CML) Interferon-a Vs. Allogeneic Stem Cell Transplantation Vs. High-Dose Chemotherapy Followed By Autografting And Interferon-a Maintainance In Early Chronic Phase Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
3 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
5 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
6 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
7 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
8 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
9 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
12 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
13 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
14 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
15 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
16 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
17 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
18 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
19 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
20 Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
21 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
22 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
23 Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies Completed NCT00627666 Phase 2 busulfan;fludarabine phosphate;leucovorin calcium;methotrexate
24 Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial Completed NCT00068276 Phase 2
25 A Phase II Study on the Effectiveness of Thalomid (Thalidomide) Combined With Procrit (Erythropoietin) for the Treatment of Anemia in Patients With Low and Intermediate Risk-1 (IPSS Score Less Than or Equal to 1.5) Myelodysplastic Syndromes Completed NCT00053001 Phase 2 thalidomide
26 A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers Completed NCT00042822 Phase 2 romidepsin
27 A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (THALOMID) For The Treatment Of Anemia In Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes Completed NCT00030550 Phase 2 thalidomide
28 Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS) Completed NCT00022048 Phase 1, Phase 2
29 Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies Completed NCT00014495 Phase 1, Phase 2 cytarabine
30 A Phase II Study of VNP40101M For Patients With Acute Myelogenous Leukemia Or High-Risk Myelodysplasia Completed NCT00083187 Phase 2 hydroxyurea;laromustine
31 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
32 A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes Completed NCT00045305 Phase 2 Cyclosporine;Methotrexate;Photopheresis;Mycofenolate mofetil;Pentostatin
33 A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies Completed NCT00014469 Phase 2 busulfan;melphalan;methotrexate;tacrolimus
34 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
36 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
37 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
38 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
39 Phase II Trial Of Non-Myeloablative Regimen Combining Melphalan, Fludarabine, And Anti-CD52 Monoclonal Antibody (CAMPATH-1H) Followed By An Unmodified Hematopoietic Cell Transplant From An HLA Compatible Related Or Unrelated Donor For Treatment Of Lymphohematopoietic Malignancies Completed NCT00027560 Phase 2 cyclosporine;fludarabine phosphate;melphalan
40 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
41 A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor Completed NCT00002718 Phase 2 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
42 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
43 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
44 Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
45 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
46 Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC) Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
47 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
48 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
49 Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes Completed NCT00052832 Phase 2
50 Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes Completed NCT00003961 Phase 2

Search NIH Clinical Center for Atypical Chronic Myeloid Leukemia

Cochrane evidence based reviews: leukemia, myeloid, chronic, atypical, bcr-abl negative

Genetic Tests for Atypical Chronic Myeloid Leukemia

Genetic tests related to Atypical Chronic Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Atypical Chronic Myeloid Leukemia 29

Anatomical Context for Atypical Chronic Myeloid Leukemia

MalaCards organs/tissues related to Atypical Chronic Myeloid Leukemia:

Myeloid, Bone, Bone Marrow, Neutrophil, T Cells, Thyroid, Liver

Publications for Atypical Chronic Myeloid Leukemia

Articles related to Atypical Chronic Myeloid Leukemia:

(show top 50) (show all 143)
# Title Authors PMID Year
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. 61
31904665 2020
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia. 61
31807857 2020
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. 61
31880950 2019
Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene. 61
31327842 2019
Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia. 61
31692115 2019
Testicular involvement without testicular enlargement in a young male with atypical chronic myeloid leukemia. 61
31276287 2019
Atypical chronic myeloid leukemia achieving good response with azacitidine. 61
31607707 2019
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). 61
31102420 2019
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. 61
30819912 2019
Characteristics and survival of patients with atypical chronic myeloid leukemia. 61
31730680 2019
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. 61
31366621 2019
Oncogenic fusion protein BCR-FGFR1 requires BCR-mediated oligomerization and chaperonin Hsp90 for activation. 61
31439673 2019
Myeloproliferative neoplasms: Diagnostic workup of the cythemic patient. 61
31069979 2019
Pulmonary alveolar proteinosis developing during steroid treatment in a patient with organizing pneumonia in association with atypical chronic myeloid leukemia. 61
30899476 2019
Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. 61
30635983 2019
[MYC gene amplification attributed to double minutes in a patient with atypical chronic myeloid leukemia]. 61
31839631 2019
The mutational landscape of atypical chronic myeloid leukemia. 61
31217789 2019
Current and evolving understanding of atypical chronic myeloid leukemia. 61
30078497 2019
Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). 61
30555034 2019
Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. 61
31112981 2019
Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review. 61
31194134 2019
Two myeloid leukemia cases with rare FLT3 fusions. 61
30559310 2018
Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. 61
30458320 2018
Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase. 61
29227326 2018
Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia. 61
29982327 2018
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. 61
29875417 2018
A typical atypical chronic myeloid leukemia. 61
29744086 2018
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. 61
29468060 2018
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. 61
29455651 2018
Atypical chronic myeloid leukemia: a rare entity with management challenges. 61
29226717 2018
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. 61
28983816 2017
Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq. 61
29025591 2017
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. 61
28927137 2017
Somatic SETBP1 mutations in myeloid neoplasms. 61
28447248 2017
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. 61
28314085 2017
Atypical chronic myeloid leukemia in a German Shepherd Dog. 61
28205462 2017
Leukemia cutis presenting as scaly plaques in a Christmas tree distribution in a patient with atypical chronic myeloid leukemia. 61
27853001 2017
Genomics of chronic neutrophilic leukemia. 61
28028025 2017
Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. 61
27789332 2017
How I treat atypical chronic myeloid leukemia. 61
27899359 2017
SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome. 61
29225884 2017
An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. 61
27664113 2016
Activity of single-agent decitabine in atypical chronic myeloid leukemia. 61
26378157 2016
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation. 61
28666496 2016
Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. 61
27807503 2016
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. 61
26475333 2016
Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. 61
26274939 2016
Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases. 61
26870268 2016
[Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia]. 61
27459623 2016
Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. 61
26870618 2015

Variations for Atypical Chronic Myeloid Leukemia

ClinVar genetic disease variations for Atypical Chronic Myeloid Leukemia:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FLT3 , MYO18A t(13;17)(q12.2;q11.2)Translocation Likely pathogenic 590265 13:28608270-28608271

Expression for Atypical Chronic Myeloid Leukemia

Search GEO for disease gene expression data for Atypical Chronic Myeloid Leukemia.

Pathways for Atypical Chronic Myeloid Leukemia

GO Terms for Atypical Chronic Myeloid Leukemia

Cellular components related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.77 U2AF1L4 U2AF1 SRSF2 SETBP1 RUNX1 RARS1
2 receptor complex GO:0043235 9.55 RYK PDGFRB PDGFRA FGFR1 CSF3R
3 nucleus GO:0005634 9.55 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 RYK
4 U2AF GO:0089701 9.26 U2AF1L4 U2AF1

Biological processes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.99 RYK PDGFRB PDGFRA JAK2 FGFR1 ABL1
2 positive regulation of cell proliferation GO:0008284 9.98 PTHLH PDGFRB PDGFRA JAK2 FGFR1
3 MAPK cascade GO:0000165 9.88 PDGFRB PDGFRA JAK2 FGFR1
4 phosphorylation GO:0016310 9.87 RYK PDGFRB PDGFRA JAK2 FGFR1 ETNK1
5 mRNA export from nucleus GO:0006406 9.79 U2AF1L4 U2AF1 SRSF2
6 mRNA 3'-end processing GO:0031124 9.72 U2AF1L4 U2AF1 SRSF2
7 phosphatidylinositol-mediated signaling GO:0048015 9.71 PDGFRB PDGFRA FGFR1
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.71 RYK PDGFRB PDGFRA FGFR1
9 skeletal system morphogenesis GO:0048705 9.67 RYK PDGFRA FGFR1
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 PDGFRB PDGFRA JAK2 FGFR1
11 RNA export from nucleus GO:0006405 9.65 U2AF1L4 U2AF1 SRSF2
12 protein autophosphorylation GO:0046777 9.65 PDGFRB PDGFRA JAK2 FGFR1 ABL1
13 cardiac myofibril assembly GO:0055003 9.61 PDGFRB PDGFRA
14 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.61 PDGFRB JAK2
15 negative regulation of cell-cell adhesion GO:0022408 9.6 JAK2 ABL1
16 hematopoietic stem cell proliferation GO:0071425 9.59 RUNX1 ETV6
17 regulation of myeloid cell differentiation GO:0045637 9.57 RUNX1 CSF3R
18 retina vasculature development in camera-type eye GO:0061298 9.56 PDGFRB PDGFRA
19 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.52 PDGFRB ABL1
20 metanephric glomerular capillary formation GO:0072277 9.46 PDGFRB PDGFRA
21 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.43 PDGFRB PDGFRA
22 positive regulation of phospholipase C activity GO:0010863 9.33 PDGFRB PDGFRA FGFR1
23 platelet-derived growth factor receptor signaling pathway GO:0048008 9.26 PDGFRB PDGFRA JAK2 ABL1
24 peptidyl-tyrosine phosphorylation GO:0018108 9.1 RYK PDGFRB PDGFRA JAK2 FGFR1 ABL1

Molecular functions related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 U2AF1 TET2 SRSF2 SETBP1 RYK RUNX1
2 ATP binding GO:0005524 9.97 RYK RUNX1 RARS1 PDGFRB PDGFRA JAK2
3 protein kinase activity GO:0004672 9.85 RYK PDGFRB PDGFRA JAK2 FGFR1 ABL1
4 nucleotide binding GO:0000166 9.83 RARS1 PDGFRB PDGFRA JAK2 FGFR1
5 kinase activity GO:0016301 9.8 RYK PDGFRB PDGFRA JAK2 FGFR1 ETNK1
6 SH2 domain binding GO:0042169 9.58 JAK2 FGFR1 ABL1
7 platelet-derived growth factor receptor binding GO:0005161 9.52 PDGFRB PDGFRA
8 platelet-derived growth factor binding GO:0048407 9.51 PDGFRB PDGFRA
9 peptide hormone receptor binding GO:0051428 9.49 PTHLH JAK2
10 pre-mRNA 3'-splice site binding GO:0030628 9.48 U2AF1L4 U2AF1
11 vascular endothelial growth factor binding GO:0038085 9.46 PDGFRB PDGFRA
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.26 RYK PDGFRB PDGFRA FGFR1
13 protein tyrosine kinase activity GO:0004713 9.1 RYK PDGFRB PDGFRA JAK2 FGFR1 ABL1

Sources for Atypical Chronic Myeloid Leukemia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....